(Q44162106)

30 November 2017

title

Free analyte QC concept: a novel approach to prove correct quantification of free therapeutic protein drug/biomarker concentrations (English)

1 reference

30 November 2017

0 references

Roland F Staack

1

1 reference

30 November 2017

Gregor Jordan

series ordinal

2

1 reference

30 November 2017

Uwe Dahl

series ordinal

3

1 reference

30 November 2017

Julia Heinrich

series ordinal

4

1 reference

30 November 2017

publication date

27 November 2013

1 reference

30 November 2017

1 reference

30 November 2017

volume

6

1 reference

30 November 2017

issue

4

1 reference

30 November 2017

page(s)

485-496

1 reference

Mathematical simulations for bioanalytical assay development: the (un-)necessity and (im-)possibility of free drug quantification

30 November 2017

cites work

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

PK-PD modeling of protein drugs: implications in assay development

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Theoretical analysis of interplay of therapeutic protein drug and circulating soluble target: temporal profiles of 'free' and 'total' drug and target

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Method validation and application of protein biomarkers: basic similarities and differences from biotherapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Qualification of a free ligand assay in the presence of anti-ligand antibody Fab fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Therapeutic monoclonal antibody concentration monitoring: free or total?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Life cycle management of critical ligand-binding reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Critical ligand binding reagent preparation/selection: when specificity depends on reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Matrix effect and recovery terminology issues in regulated drug bioanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Matrix effects in clinical immunoassays and the effect of preheating and cooling analytical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Application and interpretation of free and total drug measurements in the development of biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Effects of an endurance cycling competition on resting serum insulin-like growth factor I (IGF-I) and its binding proteins IGFBP-1 and IGFBP-3

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.316

21 January 2018

Identifiers

DOI

10.4155/BIO.13.316

1 reference

30 November 2017

1 reference